C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2026)

C4 Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$13.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 216.9% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at $10.0 million (up 126.02% YoY), while the FY2025 annual figure was $19.1 million, up 126.87% from the prior year.
• Net Cash Flow was -$13.3 million for Q1 2026 at C4 Therapeutics, down from $15.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $65.6 million in Q4 2023 to a low of -$36.9 million in Q1 2024.
• Historically, Net Cash Flow has averaged -$863882.4 across 5 years, with a median of -$4.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 287.26% in 2024, then jumped 480.58% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$19.8 million in 2022, then jumped by 431.4% to $65.6 million in 2023, then sank by 106.33% to -$4.1 million in 2024, then surged by 480.58% to $15.8 million in 2025, then plunged by 184.39% to -$13.3 million in 2026.
• The last three Net Cash Flow figures came in at -$13.3 million (Q1 2026), $15.8 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.